Finance

Lists
Outlook: 40.0% bullish·0.0% bearish
Go to analysis
VTRS:NASDAQ
Viatris Inc
17,64 USD
+1,15%
(+0,20) 1D
17,33 USD
-1,77% (-0,31)
After hours
Closed: 9-окт., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VTRS...
Open
17,36 USD
High
17,76 USD
Low
17,18 USD
Mkt. cap
20,26 млд
Avg. vol.
8,77 млн
Volume
8,83 млн
Dividend
2,72%
Quarterly dividend
0,12 USD
Ex-dividend date
2026-ж., 21-авг.
52-wk high
18,43 USD
52-wk low
9,69 USD
EPS
-0,36 USD
Beta
0,86
Shares outstanding
1,15 млд
No. of employees
30 миң
Open
17,36 USD
High
17,76 USD
Low
17,18 USD
Mkt. cap
20,26 млд
Avg. vol.
8,77 млн
Volume
8,83 млн
Dividend
2,72%
Quarterly dividend
0,12 USD
Ex-dividend date
2026-ж., 21-авг.
52-wk high
18,43 USD
52-wk low
9,69 USD
EPS
-0,36 USD
Beta
0,86
Shares outstanding
1,15 млд
No. of employees
30 миң
News stories
From web sources and news partners
Profile
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020. The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community. Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies. Wikipedia
About Viatris Inc
CEOScott A. Smith
Employees30 миң
Founded2020-ж., 16-ноя.
HeadquartersКанонсберг, Пенсильвания, Америка Кошмо Штаттары
SectorPharmaceutical industry
Analyst ratings
Based on 9 analysts giving stock ratings to VTRS in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VTRS in the last 3 months.
Highest
Current 17,64 USD
26,00 USD (+47,39%)
Average
20,00 USD (+13,38%)
Lowest
13,00 USD (-26,30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Salveen Richter
Goldman Sachs
Hold
Maintained
20,00 USD
+13,4%
10/08/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
16,00 USD
-9,3%
10/08/2026
Ashwani Verma
UBS
Buy
Maintained
26,00 USD
+47,4%
10/05/2026
Les Sulewski
Oppenheimer
Buy
Initiated
25,00 USD
+41,7%
09/23/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
25,00 USD
+41,7%
09/23/2026
David Amsellem
Piper Sandler
Hold
Reiterated
13,00 USD
-26,3%
09/16/2026
Daniel Clark
Leerink Partners
Buy
Initiated
20,00 USD
+13,4%
09/09/2026
Jasper Hellweg
Argus Research
Buy
Maintained
20,00 USD
+13,4%
09/08/2026
Glen Santangelo
Barclays
Buy
Reiterated
22,00 USD
+24,7%
08/17/2026
Chris Schott
J.P. Morgan
Hold
Maintained
18,00 USD
+2%
08/10/2026
Unknown Analyst
Jefferies
Buy
Maintained
17,00 USD
-3,6%
03/20/2026
Last report
2026-ж., 6-авг.
Fiscal period
Q2 2026
0,69 USD / 0,60 USD
+15,04%beat
Revenue / Est. (USD)
3,76 млд / 3,67 млд
+2,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
3,76 млд
3,70 млд
3,52 млд
3,76 млд
Cost of goods sold
2,26 млд
2,21 млд
2,14 млд
2,19 млд
Cost of revenue
2,26 млд
2,21 млд
2,14 млд
2,19 млд
Research and development expenses
244,80 млн
271,20 млн
245,80 млн
245,20 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
848,50 млн
933,40 млн
893,40 млн
855,00 млн
Operating expense
1,09 млд
1,20 млд
1,14 млд
1,10 млд
Total operating expenses
3,36 млд
3,42 млд
3,28 млд
3,29 млд
Operating income
404,60 млн
288,20 млн
238,60 млн
471,50 млн
Other non operating income
-135,90 млн
44,90 млн
-1,80 млн
14,40 млн
EBT including unusual items
-7,90 млн
-343,00 млн
-247,30 млн
-64,00 млн
EBT excluding unusual items
318,70 млн
188,00 млн
146,20 млн
365,40 млн
Income tax expense
120,30 млн
-2,90 млн
-423,70 млн
54,80 млн
Effective tax rate
-1 522,78%
0,85%
171,33%
-85,62%
Other operating expenses
-
-
-
-
Net income
-128,20 млн
-340,10 млн
176,40 млн
-118,80 млн
Net profit margin
-3,41%
-9,18%
5,02%
-3,16%
Earnings per share
0,67
0,57
0,59
0,69
Interest and investment income
-
-
-
-
Interest expense
-119,60 млн
-119,60 млн
-120,10 млн
-120,70 млн
Net interest expenses
-119,60 млн
-119,60 млн
-120,10 млн
-120,70 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,09 млд
981,10 млн
914,70 млн
1,14 млд
Gain or loss from assets sale
-1,60 млн
21,90 млн
13,90 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору